Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro cell line and in vivo animal research combined with retrospective database analysis
PubMed 24355709 · doi:10.1093/brain/awt333
What was done
Researchers evaluated thymosin β4 expression across glioma tissue microarrays, REMBRANDT, and The Cancer Genome Atlas (TCGA) databases, as well as in seven glioma cell lines and seven glioma-initiating cell lines. Using lentiviral vectors, they silenced or overexpressed thymosin β4 in LNT-229, U87MG, and GS-2 glioma cells. They evaluated downstream effects on gene expression, clonogenicity, migration, invasion, starvation-induced cell death, self-renewal, differentiation, and in vivo tumorigenicity and survival in mouse models.
What was found
Thymosin β4 expression increased with higher glioma malignancy grade. Knockdown of thymosin β4 in LNT-229 and U87MG cells reduced cell migration and invasion, elevated starvation-induced cell death in vitro, and prolonged survival in glioma-bearing mice. In GS-2 stem-like cells, silencing suppressed self-renewal, triggered differentiation, and decreased in vivo tumorigenicity. Gene expression profiling associated thymosin β4 with mesenchymal gene signatures and modulation of TGFβ and p53 pathways. The abstract reports no numerical values or statistical parameters.
Why it matters
This study identifies thymosin β4 as a molecular driver of glioblastoma stemness and invasiveness, highlighting it as a potential target for therapeutic development in malignant gliomas.
Limits
The study is restricted to preclinical in vitro and animal models, and clinical relevance in human patients remains unproven. The abstract omits sample sizes for human tissue arrays and animal cohorts, as well as quantitative effect sizes and p-values.
Cited by
- supports Thymosin beta-4 is a 43-amino-acid peptide being researched in oncology due to its implication in glioblastoma.